Southern Archipelago (A33) H1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2025 earnings summary
5 Nov, 2026Executive summary
1H2025 revenue was S$2.212m, down 5% YoY; the period recorded a net loss of S$566k versus net profit of S$24k in 1H2024.
Sterilisation remained the main operating contributor, while capacity expansion increased staffing and consumables costs; completion is expected in H2 2025.
Financial highlights
Revenue from sterilisation services was S$2.212m, down from S$2.337m YoY.
Loss before tax was S$254k versus profit before tax of S$283k; net loss was S$566k versus net profit of S$24k.
Other losses, net, were S$82k versus gains of S$324k; 1H2025 included a S$828k dormant-subsidiary liquidation loss, offset partly by S$674k net currency exchange gain.
Operating cash flow was S$134k versus cash used of S$245k; cash and cash equivalents ended at S$443k versus S$1.564m in 1H2024.
Outlook and guidance
Sterilisation capacity expansion is expected to be completed in H2 2025; management expects the segment to improve and continue generating positive operating cash flow.
The 12-month going-concern assessment assumes positive sterilisation operating cash flow and access to additional working capital through potential financing options.
Latest events from Southern Archipelago
- Sterilisation recovery continues, but liquidity strains and a covenant breach cloud the outlook.A33
Q3 2026 - Revenue and net profit improved, but liquidity and diversification remain key challenges.A33
H2 2023 - A return to modest profit meets weaker revenue and widening working-capital pressure.A33
H1 2024 - Sterilisation expansion continued as lower revenue, a net loss and tight liquidity shaped FY2024.A33
H2 2024 - Revenue fell 17.8%; upgraded capacity meets a strained balance sheet and recovery test.A33
H2 2025 - Revenue fell 47% amid Indonesian headwinds, with liquidity and covenant risks still acute.A33
Q1 2026 - Sterilisation rebounded in 2Q, but liquidity pressure and a loan covenant breach persist.A33
H1 2026